Instil Bio (Instil Bio) Earnings per Share (Diluted)

: $-24.00 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Instil Bio's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-2.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.00.

Instil Bio's EPS (Basic) for the three months ended in Dec. 2023 was $-2.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.00.

Instil Bio's EPS without NRI for the three months ended in Dec. 2023 was $-1.98. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.39.

Instil Bio Earnings per Share (Diluted) Historical Data

The historical data trend for Instil Bio's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instil Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

-2.11

-6.10

-29.60

-34.46

-24.00

Instil Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)													-8.20	-8.80	-2.80	-10.40	-2.00

Competitive Comparison

For the Biotechnology subindustry, Instil Bio's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instil Bio PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Instil Bio's PE Ratio distribution charts can be found below:

* The bar in red indicates where Instil Bio's PE Ratio falls into.

Instil Bio Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Instil Bio's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-156.087	-	0)	/	6.504
	=	-24.00

Instil Bio's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-12.925	-	0)	/	6.504
	=	-1.99

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.00

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Instil Bio (NAS:TIL) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Instil Bio Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Instil Bio's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Instil Bio (Instil Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Instil Bio Inc (NAS:TIL) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219

Website

https://www.instilbio.com

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.

Executives

Timothy L. Moore	officer: Chief Operating Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Sumita Ray	officer: Chief Legal and Admin Officer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Nimish P Shah	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jack Nielsen	director, 10 percent owner	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Mcgaughy R Kent Jr	director	500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Curative Ventures V Llc	10 percent owner	3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219
Bronson Crouch	director, 10 percent owner, officer: CEO and Chairman	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vivo Capital Ix, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Sandeep Laumas	officer: CFO and CBO	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Gwendolyn Binder	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Zachary Roberts	officer: Chief Medical Officer	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
George Matcham	director	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vijay Chiruvolu	officer: Chief Technical Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037